View all studies | NASH - Advanced Fatty Liver

NASH Research Study

The hidden epidemic you need to know about.

NASH, short for Nonalcoholic Steatohepatitis, is an advanced nonalcoholic fatty liver disease characterized by a buildup of fat on the liver that can cause permanent damage hindering its ability to filter the blood. It’s estimated that 16 million Americans have been diagnosed with NASH, with many more likely undiagnosed. Currently, it’s the second leading cause of liver transplants in the US. A noninvasive liver FibroScan® (similar to an ultrasound) can be done to determine a probable diagnosis, but should be confirmed by a biopsy. Risk factors include: type 2 diabetes, high cholesterol, and obesity with an accumulation of fat around the midsection.

Right now, there are no medications currently approved for treating NASH. Accellacare is enrolling studies that may lead to the first approved treatment. Eligible participants will receive study-related care and study medication at no cost. 

Submit to learn more:

When you register your interest with Accellacare, our clinical research specialists will review your information at no cost and connect you with studies you may be eligible for. When we find a match, Accellacare may contact you for further pre-screening or we may share your information with a local site office for them to contact you directly. Your data will be processed as outlined in the Accellacare Privacy Notice.

Data Protection

As the data controller for the Improvingtreatments.co.uk, Accellacare is committed to protecting the information that you provide. Where you give us your consent, we may use your information to: (a) identify appropriate clinical trials for you and to let you know about them; and/or (b) send you invitations to participate in future study opportunities. You can withdraw your consent at any time, but we may continue some limited processing where we have other legal grounds for doing so.

Please enter the security code:


Please note: You may or may not benefit medically from taking part and you are able to opt out at anytime and do not have to give us a reason for doing so. Your primary care physician will be informed about your participation and all medical assessments that will be carried out as part of the study. If during screening any abnormal results are found your primary care physician will also be informed.